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3D Molecular modelingAbstract The synthesis of ﬁve new chelates of copper(II) of the general formula [Cu(LH)2(Cl)2],
where LH= N-(40-butyrylidine-30-methyl-10-phenyl-20-pyrazolin-50-one)sulfamethoxazole (bumphp-
smzH, I), N-(40-butyrylidine-30-methyl-10-phenyl-20-pyrazolin-50-one)sulfadimidine (bumphp-sdmH,
II), N-(40-butyrylidine-30-methyl-10-phenyl-20-pyrazolin-50-one)sulfanilamide (bumphp-snmH, III),
N-(40-butyrylidine-30-methyl-10-phenyl-20-pyrazolin-50-one)sulfamoxole (bumphp-smlH, IV) or N-
(40-butyrylidine-30-methyl-1’-phenyl-20-pyrazolin-50-one)sulfaguanidine (bumphp-sgdH, V) has been
carried out. The complexes have been characterized by elemental analyses, copper determination,
molar conductance, magnetic and decomposition temperature measurements, electron spin reso-
nance, thermogravimetry, infrared, and electronic spectral studies. A trans octahedral structure has
been proposed for these complexes. The 3D molecular modeling and analysis for bond lengths and
bond angles have also been carried out for one of the representative compound, [Cu(bumphp-
snmH)2(Cl)2] (3) to substantiate the proposed structure.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
4-Acyl-3-methyl-1-phenyl-2-pyrazolin-5-ones belong to a fam-
ily of heterocyclic b-diketones, and are comparable to b-dike-
tones because in both classes keto-enol tautomerism is
possible. Such ligands have played and continue to play a part
in the development of coordination compounds that have
found a wide application in several ﬁelds (Marchetti et al.,
144 R.C. Maurya et al.2005), from new materials to catalysts, as precursors for CVD
in the microelectronic industry and as potential antitumorals.
The 5-pyrazolone derivatives have been extensively investi-
gated due to their wide range of pharmacological activities
(Alaudeen et al., 2003).
Sulfonamide derivatives exhibit a range of bioactivities,
including anti-angiogenic (Funahashi et al., 2002; Semba
et al., 2004), anti-tumor (Semba et al., 2004; Sawi´nski and
Gdaniec, 2005), anti-inﬂammatory and anti-analgesic (Chen
et al., 2005), anti-tubercular (Gadad et al., 2004), anti-glau-
coma (Agrawal et al., 2004), anti-HIV (Yeung et al., 2005),
cytotoxic (Enc´ıo et al., 2005), anti-microbial (Nieta et al.,
2005) and anti-malarial (Dom´ınguez et al., 2005) agents.
Sulfonamide derivatives are also known to exhibit a wide vari-
ety of pharmacological activities (Yoshino et al., 1992; Toth
et al., 1997; Medina et al., 1999) through exchanges of different
functional groups without modiﬁcation of the structural –
S(O)2N(H)– feature. The synthesis of metal sulfonamide com-
pounds had received much attention due to the fact that sul-
fanilamides were the ﬁrst effective chemotherapeutic agents
to be employed for the prevention and cure of bacterial infec-
tions in humans (Mohamed and Gad-Elkareem, 2007). The
pharmacological activity of these types of molecules is often
enhanced by complexation with metal ions (Bult and Sigel,
1983; Casanova et al., 1983). Moreover, some metal complexes
of these ligands have been found to promote rapid healing of
burns in humans and animals (De Oliveira et al., 2008). The
effectiveness of burn treatment seems to depend not only on
the presence of the metal ion but also crucially on the nature
of the material to which the metal ion is bound (Baenziger
et al., 1983).
Within the last decade there has been an upsurge of interest
in metal ion therapeutics for both diagnosis and treatment
(Schwietert and McCue, 1999; Deschamps et al., 2005). For
example Cu(II)-L-histidine (Sarkar, 1999) has been used in
the treatment of Menkes disease (Danks et al., 1995; Weder
et al., 2002). Such interest has been due to the biochemical
and pharmacological properties of the metal-ligand system,
with extensive research carried out to determine the role of
the ligand in copper uptake into cells. On the other hand many
research papers (Dillion et al., 2003; Zvimba and Jackson,
2007) that have indicated the effective role of various copper
chelating agents in the alleviation of inﬂammation associated
with rheumatoid arthritis (RA) have also indicated the physio-
logical importance of these agents as well as their therapeutic
applications.
The number of people suffering from diabetes mellitus
(DM) has been showing an annual increase. The patients with
type I DM require daily insulin injections, which is both a
physical and mental burden. Furthermore, DM leads to ser-
ious life-threatening complications causing severe damage to
several organs such as, heart, eyes, kidneys, blood vessels,
nerves, gums, teeth, feet, and legs (Marshall, 2004; Ritz and
Haxsen, 2005; Moore et al., 1999). Thus, there is an urgent
need to establish a treatment regime that can replace painful
insulin injections. Since 1980 many researchers have attempted
to identify alternative anti-diabetic compounds and have
reported that metal ions such as vanadium (Shechter and
Karlish, 1980; Sakurai et al., 2002), zinc (Coulston and
Dandona, 1980), manganese (Fonteles et al., 2000), copper
(Sorenson and Prog, 1989), chromium (Anderson et al.,
1997), and tungsten (Munoz et al., 2001) exhibit in vitroinsulinomimetic activity and in vivo anti-diabetic ability in
experimental animals. In a recent report, a copper(II) chelate
in O,N-donor coordination environment involving picolinic
acid has been reported as a potent diabetic agent
(Yasumatsu et al., 2007).
Previous reports from our laboratory describe the synthesis
and characterization of mononuclear ruthenium(II) chelates
with some Schiff base ligands derived from sulfa drugs and
4-benzoyl-3-methyl-1-phenyl-2-pyrazolin-5-one (Maurya
et al., 1994). Synthesis, magnetic, and spectral studies of some
novel binuclear dioxomolybdenum(VI) chelates involving
Schiff bases derived from sulfa drugs and 4-benzoyl-3-
methyl-1-phenyl-2-pyrazolin-5-one have been recently
reported by Maurya et al. (2004). Four new
oxovanadium(IV) complexes, formed by the interaction of
vanadyl sulfate pentahydrate and the Schiff bases derived from
3-methyl-1-phenyl-4-valeryl-2-pyrazolin-5-one and sulfa drugs
viz., N-(30-methyl-10-phenyl-40-valerylidene-20-pyrazolin-50-
one)sulfadiazine (L1H), N-(30-methyl-10-phenyl-40-valeryli-
dene-20-pyrazolin-50-one (L2H), N-(30-methyl-10-phenyl-40-
valerylidene-20-pyrazolin-50-one)sulfanilamide (L3H), and N-
(30-methyl-10-phenyl-40-valerylidene-20-pyrazolin-50-one)sul-
famethoxazole (L4H) in aqueous ethanol are described by
Maurya and Rajput (2006). Some new mixed-ligand ternary
complexes of Cu(II), Ni(II), Co(II), Zn(II), Sm(III), Th(IV),
and U(VI)O2 with the Schiff base derived from salicylaldehyde
and the sulfa drug sulfabenzamide, [N-(salicylidene)-sul-
fabenzamide] (LH) and the heterocyclic base 1,10-phenanthro-
line (phen) have been reported by Maurya et al. (2007). Four
new dioxomolybdenum(VI) chelates of the general composi-
tion, [MoO2(L)2(H2O)3], where LH= N-(o-vanillidene)sul-
fadiazine (vsdzH), N-(o-vanillidene)sulfanilamide (vsnmH),
N-(o-vanillidene)sulfaguanidine (vsgnH), N-(o-vanillidene)sul-
famerazine (vsmrH) were recently reported by Maurya et al.
(in press, 2015).
In view of the multiple importance of copper(II) complexes
mentioned above, it was, therefore, thought worthwhile to syn-
thesize and characterize some copper(II) complexes with Schiff
bases derived from 4-butyryl-3-methyl-1-phenyl-2-pyrazolin-5-
one and sulfa drugs, viz., N-(40-butyrylidine-30-methyl-10-phe-
nyl-20-pyrazolin-50-one)sulfamethoxazole (bumphp-smzH, I),
N-(40-butyrylidine-30-methyl-10-phenyl-20-pyrazolin-50-one)sul-
fadimidine (bumphp-sdmH, II), N-(40-butyrylidine-30-methyl-
10-phenyl-20-pyrazolin-50-one)sulfanilamide (bumphp-snmH,
III), N-(40-butyrylidine-30-methyl-10-phenyl-20-pyrazolin-50-
one)sulfamoxole (bumphp-sml, IV) or N-(40-butyrylidine-
3 0-methyl-1 0-phenyl-2 0-pyrazolin-5 0-one)sulfaguanidine
(bumphp-sgd, V) (Fig. 1), not reported hitherto. The results of
our studies in this investigation are presented in this paper.
2. Experimental
2.1. Materials
3-Methyl-1-phenyl-2-pyrazolin-5-one was the product of
Johnson Chemical Co., Mumbai. The sulfa drugs, viz., sul-
famethoxazole, sulfadimidine, sulfanilamide, sulfamoxole and
sulfaguanidine were products of Sigma Chemical Co., USA.
Copper(II) chloride dihydrate was the product of B.D.H.
Chemicals, Mumbai, while butyryl chloride was purchased
from Aldrich Chemical Company, USA. All other chemicals
Figure 1 Reaction showing synthesis of Schiff base ligands.
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phenyl-2-pyrazolin-5-one (bumphp) was prepared by the
method reported elsewhere (Jensen, 1959).
2.2. Synthesis of sulfa drug Schiff bases
The Schiff bases with sulfa drugs were prepared as follows: an
ethanolic solution (15 mL) of bumphp (2.44 g, 0.01 mol) was
added to the solution of sulphamethoxazol (2.53 g, 0.01 mol)
in ethanol, or sulfadimidine (2.78 g, 0.01 mol) in ethanol, or
sulfanilamide (1.72 g, 0.01 mol) in acetone or sulfamoxole
(2.67 g, 0.01 mol) in ethanol or sulfaguanidine (2.14 g,
0.01 mol) in ethanol along with two drops of HCl. The result-
ing solution was reﬂuxed with stirring for 5–6 h and then ﬁl-
tered to remove the insoluble sulfa drug, if any. The ﬁltrate
so obtained was concentrated on a water bath and left over-
night at room temperature when yellow crystals of Schiff bases
separated out from their respective solutions. The crystals thus
obtained were washed with ethanol and dried in vacuo.
2.3. Synthesis of complexes
All the complexes were prepared by the general method,
namely, the salt cupric chloride dihydrate (0.001 mol,
0.170 g) was dissolved in ethanol (10 mL) by heating and the
resulting solution was added to a warmed, stirred solution of
the corresponding Schiff base, bumphp-smzH (0.002 mol,
0.958 g), bumphp-sdmH (0.002 mol, 1.8 g), bumphp-snmH
(0.002 mol, 0.796 g), bumphp-smxH (0.002 mol, 0.986 g), or
bumphp-sgdH (0.002 mol, 0.880 g) in 15 mL of ethanol. The
resulting solution was reﬂuxed for 4–5 h when the desired com-
pound separated out as a ﬁne precipitate keeping the reaction
mixture overnight. It was ﬁltered by suction, washed severaltimes with ethanol and then dried in vacuo over anhydrous cal-
cium chloride.
2.4. Analysis
Microanalysis of carbon, hydrogen, and nitrogen of the com-
plexes was performed on a Carlo Erba 1108 Heracus elemental
analyser at CDRI, Lucknow. Copper was estimated as copper
salicyladoximate (Vogel, 1962).
2.5. Physical methods
The solid-state infrared spectra were recorded in KBr pellets
with a Perkin Elmer FT-IR spectrophotometer at Central
Drug Research Institute, Lucknow. Magnetic measurements
were carried out at room temperature on vibrating sample
magnetometer at RSIC, Indian Institute of Technology,
Chennai. Electronic spectra of the complexes were recorded on
an ATI Unicam, UV-2-100 UV–Visible Spectrophotometer in
our Department. Conductance measurements were performed
at room temperature in dimethylformamide using a Toshniwal
conductivity bridge and a dip type cell with a smooth platinum
electrode of cell constant 1.02. The decomposition temperatures
of the complexes were recorded by an electrically operated melt-
ing point apparatus, Kumar Industries,Mumbai, with a heating
capacity up to 360 C. The X-Band EPR spectra of the com-
plexes weremeasured on a Bruker ESPX-band EPR spectrome-
ter using powdered samples at the Regional Sophisticated
Instrumentation Centre, Indian institute of Technology,
Chennai at the microwave frequency of 9.45 GHz.
2.6. Molecular modeling studies
The 3D molecular modeling of a representative compound was
carried out on ChemBio3D Ultra Molecular Modeling and
Analysis Program (www.cambridgesoft.com). It is an interac-
tive graphics program that allows rapid structure building,
geometry optimization with minimum energy and molecular
display. It has the ability to handle transition metal
compounds.3. Results and discussion
The Copper(II) complexes of sulpha drug Schiff bases were
prepared according to the following reaction.
CuCl2  2H2Oþ 2LH !Ethanol
Reflux
½CuðLHÞ2ðClÞ2 þ 2H2O
where LH = bumphp-smzH (1), bumphp-sdmH, (2), bumphp-
snmH (3), bumphp-smxH (4) or bumphp-sgdH (5).
The synthesized complexes are colored (Table 2), non-hy-
groscopic and air stable solids. They are soluble in dimethyl-
formamide and insoluble in ethanol and methanol. The
resulting complexes were characterized using the following
physical studies.
3.1. Infrared spectral studies
The sulfa drug based Schiff base ligands used in the present
investigation were synthesized by the scheme as shown in
Table 1 Characterization data and important IR spectral bands, (cm1) of synthesized Schiff bases.
Sr. No. Schiﬀ base (empirical formula)
(formula weight)
Found (Calcd), % Yield (%) m(C‚O) m(C‚N)
(azomethine)
m(N–H) mas(S‚O2) ms(S‚O2)
C H N
(I) Bumphp-smzH 60.25 5.14 14.38 55 1660 s 1608 s 3420 br 1382 m 1158 m
(C24H25N5O4S) (479) (60.13) (5.22) (14.61)
(II) Bumphp-sdmH 61.68 5.68 16.36 50 1665 s 1605 s 3430 br 1382 m 1160 m
(C26H28N6O3S) (504) (61.90) (5.56) (16.67) 3335
(III) Bumphp-snmH 60.15 5.48 4.19 50 1670 s 1609 s 3425 br 1381 m 1187 m
(C20H22N4O3S (398) (60.30) (5.53) (14.07)
(IV) Bumphp-smxH 60.63 5.40 14.08 55 1652 s 1607 s 3410 br 1380 m 1183 m
(C25H27N5O4S) (493) (60.85) (5.48) (14.20)
(V) Bumphp-sgdH 57.42 5.27 19.22 52 1670 s 1610 s 3430 br 1369 m 1179 m
(C21H24N6O3S) (440) (57.27) (5.45) (19.09) 3342
Table 2 Analytical data, colors, % yields and decomposition temperatures of the synthesized complexes.
Sr. No. Compound (empirical formula)
(formula weight)
Found (Calcd), % Color Yield (%) Decom.
Temp (C)
C H N Cu
(1) [Cu(bumphp-smzH)2(Cl)2] 52.45 4.22 12.53 5.43 Pastel green 53 275
(C48H50Cl2N10O8S2Cu) (1092.54) (52.72) (4.58) (12.81) (5.82)
(2) [Cu(bumphp-sdmH)2(Cl)2] 54.43 4.90 14.49 5.83 Venetian green 55 270
(C52H56Cl2N12O6S2Cu) (1142.54) (54.62) (4.90) (14.70) (5.56)
(3) [Cu(bumphp-snmH)2(Cl)2] 51.35 4.62 12.23 6.53 Lime 52 285
(C40H44Cl2N8O6S2Cu) (930.54) (51.58) (4.73) (12.04) (6.83)
(4) [Cu(bumphp-smxH)2(Cl)2] 53.45 4.42 12.73 5.39 Lime 50 295
(C50H52Cl2N10O8S2Cu) (1120.54) (53.55) (4.82) (12.49) (5.67)
(5) [Cu(bumphp-sgd)2(Cl)2] 49.45 4.62 16.33 6.73 Lime 54 280
(C42H48Cl2N12O6S2Cu) (1012.54) (49.68) (4.73) (16.56) (6.26)
Table 3 Important IR spectral bands (cm1) and their assignment, and some physical properties of the synthesized complexes.
Sr. No. Compound m(C‚O) m(C‚N) m(Cu–O) m(Cu–N) Km (Ohm
1 cm2 mol1) leﬀ (BM)
(1) [Cu(bumphp-smzH)2(Cl)2] 1607 vs 1577 s 510 w 427 w 7.2 1.81
(2) [Cu(bumphp-sdmH)2(Cl)2] 1607 vs 1580 s 510 w 416 w 10.2 1.84
(3) [Cu(bumphp-snmH)2(Cl)2] 1607 vs 1582 s 512 w 489 w 8.6 1.82
(4) [Cu(bumphp-smxH)2(Cl)2] 1609 vs 1578 s 510 w 419 w 9.5 1.85
(5) [Cu(bumphp-sgd)2(Cl)2] 1623 vs 1582 s 557 w 490 w 10.8 1.86
146 R.C. Maurya et al.Fig. 1. The formation of the Schiff base ligands is consistent with
the microanalytical data of the ligands. The C, H, and N data,
percentage yields, and important infrared spectral bands are
given in Table 1. The formation of the Schiff base ligands is sup-
ported by the appearance of a strong band at 1625–1629 cm1
due to m(C‚N) (azomethine) in the IR spectra of these ligands.
All of the Schiff base ligands in the present investigation exhibit a
broad band centered at 3328–3440 cm1. This suggests the
involvement of the 5-OH group in the intramolecular hydrogen
(Maurya et al., 1997) bonding with the lone pair of azomethine
nitrogen. It also suggests that the ligands exist in enol form in the
solid state (Maurya et al., 1996).
The important infrared spectral bands of the complexes
along with their plausible assignments are given in Table 3.
All the Schiff base ligands used in this investigation exist in
enol form as discussed above. Hence, they possess six potential
donor sites: (i) the enolic oxygen, (ii) the cyclic nitrogen N1pyrazolone moiety, (iii) the cyclic Nitrogen N2 pyrazolone
moiety, (iv) the azomethine nitrogen, (v) sulfonamide
(SO2NH) oxygen or nitrogen and (vi) the ring nitrogen of
the sulfa drug.
The appearance of a band at 1385–1390 cm1 in the ligands
is assigned (Maurya et al., 2007) to mas(O‚S‚O). This band
remains almost at the same position in the complexes and
hence suggests that the sulfonamide oxygen is not taking part
in coordination with the metal centre.
The m(NH) mode(s) of the sulfonamide group/amino group
of the free Schiff bases, which is/are observed at 3310–3362
and 3216 cm1, remain(s) unperturbed in the spectra of their
complexes. This suggests that the sulfonamide/amino nitrogen
is not taking part in coordination.
All the ligands display a sharp and strong band due to
m(C‚N) of the azomethine group at 1625–1629 cm1. The
observed low energy shift of this band appearing in the range
Figure 2 IR spectrum of bumphp-snmH (III).
Table 4 Electronic spectral data of selected complexes.
Compound No. Compound kmax (nm) e (L cm
1 mol1) Peak assignment
(1) [Cu(bumphp-smzH)2(Cl)2] 291 3116 Charge transfer transition
441 109 2Eg‹ 2B1g
(2) [Cu(bumphp-sdmH)2(Cl)2] 288 3173 Charge transfer transition
296 3176 Charge transfer transition
420 142 2Eg‹ 2B1g
700 71 2B2g‹ 2B1g
(3) [Cu(bumphp-snmH)2(Cl)2] 288 3215 Charge transfer transition
307 3230 Charge transfer transition
325 3120 Charge transfer transition
410 135 2Eg‹ 2B1g
700 65 2B2g‹ 2B1g
(4) [Cu(bumphp-smxH)2(Cl)2] 288 3161 Charge transfer transition
400 150 2Eg‹ 2B1g
680 62 2B2g‹ 2B1g
(5) [Cu(bumphp-sgd)2(Cl)2] 291 3310 Charge transfer transition
326 3595 Charge transfer transition
430 180 2Eg‹ 2B1g
710 70 2B2g‹ 2B1g
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gests the coordination of azomethine nitrogen (Maurya et al.,
2007) to the metal centre. The coordination of enolic oxygen of
the pyrazolone moiety of the ligands after deprotonation is
most likely for the formation of six membered chelate ring
including azomethine nitrogen and the metal centre in ques-
tion, and this should be reﬂected by the disappearance of the
m(OH) mode of the ligands centered at 3328–3440 cm1.
However, the appearance of m(OH) mode in all the complexes
in the same region suggests the coordination of the enolic oxy-
gen without deprotonation. One of the of the possibilities of
the presence of m(OH) mode in the complexes may be due tolattice or coordinated water in them, but this is ruled out by
TG analysis of the complexes wherein no weight loss was
observed up to 200 C. The coordination of enolic oxygen
without deprotonation has already been observed by us
(Maurya et al., 2003a) in a mixed-ligand cyanonitrosyl com-
plexes of molybdenum(II) of the composition,
[MoII(NO)(CN)3(BMPHP)], where BMPHP= 4-benzoyl-3-
methyl-1-phenyl-2-pyrazolin-5-one, a carbonyl compound
similar to 4-butyryl-3-methyl-1-phenyl-2-pyrazolin-5-one,
which is one of the component of the Schiff base ligands used
in the present studies. The overall IR data conclude that the
sulfa Schiff bases behave as neutral bidentate (N, O) ligands.
Figure 3 IR spectrum of [Cu(bumphp-snm)2(Cl)2] (3).
Figure 4 ESR spectrum of ESR spectrum of [Cu(bumphp-smzH)2(Cl)2] (1) (a) [Cu(bumphp-sdmH)2(Cl)2] (2) (b).
Figure 5 Electronic spectrum of [Cu(bumphp-smzH)2(Cl)2] (1).
148 R.C. Maurya et al.The m(C‚N2) (cyclic) mode arising from the pyrazolone
moiety of the ligands appears at 1580–1582 cm1, and it does
not show any appreciable change in its position in the com-
plexes (see Table 3). Similarly, the m(C‚N) (cyclic) mode
due to the sulpha drug skeleton of all the ligands appearing
at 1600 cm1 remains unchanged after complexation, and
seems to be merged with m(C‚N) (azomethine). These obser-
vations indicate the non-participation of the ring nitrogen N2
of the pyrazolone moiety and the cyclic nitrogen of the sulfa
drug skeleton of the ligands in bonding. Considering the pla-
narity of the ligands, the coordination of the ring nitrogen
N2 is also unlikely due to being in the backside of the effective
donor sites, (i) and (iv) discussed above forming six membered
chelate ring including the metal. Such a result has already been
reported (Maurya and Rajput, 2006) by us. Likewise, the non-
participation of the cyclic nitrogen of the sulfa drug skeleton in
bonding may be attributed due to being too far from the suit-
able donor sites, (i) and (iv) and the central metal. The coordi-
nation of the ring nitrogen N1 is also unlikely due to a steric
demand of the bulky phenyl group attached with it.A single peak for the m(Cu–Cl) should appear at 300 cm1
in the infrared spectra of all the complexes. Unfortunately, this
peak could not be assigned due to recording of the spectra up
Figure 6 TG curve of [Cu(bumphp-smzH)2(Cl)2] (1).
Figure 7 TG curve of [Cu(bumphp-smxH)2(Cl)2] (4).
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and 416–490 have been assigned (Maurya et al., 2008) to
m(Cu–O) and m(Cu–N), respectively. The IR spectrum of a
Schiff base ligand, bumphp-snmH (III) and its complex, (3),
are given in Figs. 2 and 3, respectively.Figure 8 3D Structur3.2. Electron spin resonance spectra
The ESR spectra of polycrystalline compounds, namely,
[Cu(bumphp-smzH)2(Cl)2] (1) and [Cu(bumphp-sdmH)2(Cl)2]
(2) were recorded at room temperature at the microwave fre-
quency of 9.45 GHz. Both parallel and perpendicular features
of 63Cu are resolved in both the spectra, which are character-
istic of axial symmetry. Nuclear hyperﬁne coupling is observed
in the gk region with one component clearly resolved. Thus, it
appears that the second, third, and fourth components are
obscured by the broad g? component (Garcio-Lozano et al.,
1994). The g?, gk, and gav values for these complexes were cal-
culated as 2.074/2.079, 2.174/2.190, and 2.107/2.116, respec-
tively. The trend gk (2.174/2.190) > g? (2.074/2.079) > ge
(2.0036, free ion value) observed in these two complexes shows
that the unpaired electron is in the dx2y2 orbital of Cu(II). The
gk and g? values deviating considerably from the free ion value
are close to those reported for a number of distorted copper(II)
complexes (Maurya et al., 2003b). Moreover, the observed g
values less than 2.3, suggest the covalent (Neiman and
Kivelson, 1961) nature of metal-ligand bonds in these com-
plexes. The ESR spectra of compound (1) and (2) are given
in Fig. 4a and b, respectively.
3.3. Electronic spectra
The electronic spectra of all these compounds were recorded in
103 molar dimethylformamide solutions in the range 200–
800 nm. The kmax of electronic spectral peaks and respective
molar extinction coefﬁcients along with their tentative assign-
ments are given in Table 4. The high intensity peak(s) in all the
complexes at 288–326 nm is/are assigned as intra-ligand transi-
tion(s). Normally, octahedral copper(II) complexes exhibit a
broad band around 714–740 nm described by the transition
2T2g‹ 2Eg. However, due to distortion caused by weak axiale of compound (3).
Table 5 Various bond lengths of compound [Cu(bumphp-snmH)2(Cl)2] (3).
Sr. No. Atoms Actual bond length Optimal bond length Sr. No. Atoms Actual bond length Optimal bond length
1 C(57)–H(107) 1.1 1.1 58 N(31)–C(27) 1.26 1.456
2 C(56)–H(106) 1.1 1.1 59 C(27)–C(28) 1.3948 1.42
3 C(56)–C(57) 1.3949 1.42 60 C(26)–H(82) 1.1 1.1
4 N(59)–C(55) 1.26 1.456 61 C(26)–C(27) 1.3948 1.42
5 C(55)–C(56) 1.3948 1.42 62 C(25)–H(81) 1.1 1.1
6 C(54)–H(105) 1.1 1.1 63 C(25)–C(26) 1.3949 1.42
7 C(54)–C(55) 1.3948 1.42 64 C(24)–C(29) 1.3948 1.42
8 C(53)–H(104) 1.1 1.1 65 C(24)–C(25) 1.3948 1.42
9 C(53)–C(54) 1.3949 1.42 66 N(23)–H(80) 1.02 1.02
10 C(52)–C(57) 1.3948 1.42 67 N(23)–H(79) 1.02 1.02
11 C(52)–C(53) 1.3948 1.42 68 S(22)–O(30) 1.45 1.45
12 N(51)–H(103) 1.02 1.02 69 S(22)–C(24) 1.79 –
13 N(51)–H(102) 1.02 1.02 70 S(22)–N(23) 1.696 –
14 S(50)–O(58) 1.45 1.45 71 O(21)–S(22) 1.45 1.45
15 S(50)–C(52) 1.79 – 72 C(20)–H(78) 1.113 1.113
16 S(50)–N(51) 1.696 – 73 C(20)–H(77) 1.113 1.113
17 O(49)–S(50) 1.45 1.45 74 C(20)–H(76) 1.113 1.113
18 C(48)–H(101) 1.113 1.113 75 C(19)–H(75) 1.113 1.113
19 C(48)–H(100) 1.113 1.113 76 C(19)–H(74) 1.113 1.113
20 C(48)–H(99) 1.113 1.113 77 C(19)–C(20) 1.523 1.523
21 C(47)–H(98) 1.113 1.113 78 C(18)–H(73) 1.113 1.113
22 C(47)–H(97) 1.113 1.113 79 C(18)–H(72) 1.113 1.113
23 C(47)–C(48) 1.523 1.523 80 C(18)–C(19) 1.523 1.523
24 C(46)–H(96) 1.113 1.113 81 C(17)–N(31) 0.961 1.26
25 C(46)–H(95) 1.113 1.113 82 C(17)–C(18) 1.497 1.497
26 C(46)–C(47) 1.523 1.523 83 C(16)–H(71) 1.113 1.113
27 C(45)–N(59) 1.2185 1.26 84 C(16)–H(70) 1.113 1.113
28 C(45)–C(46) 1.497 1.497 85 C(16)–H(69) 1.113 1.113
29 C(44)–H(94) 1.113 1.113 86 C(15)–H(68) 1.1 1.1
30 C(44)–H(93) 1.113 1.113 87 C(14)–H(67) 1.1 1.1
31 C(44)–H(92) 1.113 1.113 88 C(14)–C(15) 1.3949 1.42
32 C(43)–H(91) 1.1 1.1 89 C(13)–H(66) 1.1 1.1
33 C(42)–H(90) 1.1 1.1 90 C(13)–C(14) 1.3948 1.42
34 C(42)–C(43) 1.3949 1.42 91 C(12)–H(65) 1.1 1.1
35 C(41)–H(89) 1.1 1.1 92 C(12)–C(13) 1.3948 1.42
36 C(41)–C(42) 1.3948 1.42 93 C(11)–H(64) 1.1 1.1
37 C(40)–H(88) 1.1 1.1 94 C(11)–C(12) 1.3949 1.42
38 C(40)–C(41) 1.3948 1.42 95 C(10)–C(15) 1.3948 1.42
39 C(39)–H(87) 1.1 1.1 96 C(10)–C(11) 1.3948 1.42
40 C(39)–C(40) 1.3949 1.42 97 O(9)–H(61) 0.942 0.961
41 C(38)–C(43) 1.3948 1.42 98 C(8)–H(63) 1.113 1.111
42 C(38)–C(39) 1.3948 1.42 99 C(8)–O(9) 1.402 1.41
43 O(37)–H(60) 0.942 0.961 100 C(7)–H(62) 1.113 1.113
44 C(36)–H(86) 1.113 1.111 101 C(7)–C(17) 1.497 1.497
45 C(36)–O(37) 1.402 1.41 102 C(7)–C(8) 1.523 1.514
46 C(35)–H(85) 1.113 1.113 103 C(6)–C(16) 1.497 1.497
47 C(35)–C(45) 1.497 1.497 104 C(6)–C(7) 1.497 1.497
48 C(35)–C(36) 1.523 1.514 105 N(5)–C(6) 1.5306 1.26
49 C(34)–C(44) 1.497 1.497 106 N(4)–C(10) 1.266 1.462
50 C(34)–C(35) 1.497 1.497 107 N(4)–C(8) 1.47 1.47
51 N(33)––C(34) 1.4515 1.26 108 N(4)–N(5) 1.23 1.426
52 N(32)–C(38) 1.266 1.462 109 O(37)–Cu(1) 1.81 –
53 N(32)–C(36) 1.47 1.47 110 O(9)–Cu(1) 1.81 –
54 N(32)–N(33) 1.23 1.426 111 N(59)–Cu(1) 1.303 1.303
55 C(29)–H(84) 1.1 1.1 112 N(31)–Cu(1) 1.303 1.303
56 C(28)–H(83) 1.1 1.1 113 Cu(1)–Cl(3) 2.16 –
57 C(28)–C(29) 1.3949 1.42 114 Cu(1)–Cl(2) 2.16 –
150 R.C. Maurya et al.ligands, the broad bands split distinctly into two or three
bands. Three spin-allowed transitions are theoretically possible
and are attributed to 2A1g‹ 2B1g, 2B2g‹ 2B1g, and
2Eg‹ 2B1g. But when the difference between 2A1g and 2B1g
is small, the transition 2A1g‹ 2B1g could remain unobserved.Based on the energy level diagram (Sathyanarayana, 2001)
reported elsewhere, and also considering the low intensity of
the remaining one/two d–d transition(s) in the visible region
at 400–441 and 680–710 nm is/are assigned to the transitions
2Eg‹ 2B1g and 2B2g‹ 2B1g, respectively. However, the band
Table 6 Various bond angles of compound [Cu(bumphp-snmH)2(Cl)2] (3).
Sr. No. Atoms Actual bond
angles
Optimal bond
angles
Sr. No. Atoms Actual bond
angles
Optimal bond
angles
1 H(103)–N(51)–H(102) 119.9999 104.5 106 C(46)–C(45)–C(35) 123.8202 117.2
2 H(103)–N(51)–S(50) 119.9998 – 107 H(84)–C(29)–C(28) 119.9994 120
3 H(102)–N(51)–S(50) 120.0003 – 108 H(84)–C(29)–C(24) 120.0008 120
4 H(101)–C(48)–H(100) 109.5199 109 109 C(28)–C(29)–C(24) 119.9998 –
5 H(101)–C(48)–H(99) 109.4617 109 110 O(30)–S(22)–C(24) 109.5198 –
6 H(101)–C(48)–C(47) 109.4621 110 111 O(30)–S(22)–N(23) 109.4419 –
7 H(100)–C(48)–H(99) 109.4416 109 112 O(30)–S(22)–O(21) 109.442 116.6
8 H(100)–C(48)–C(47) 109.4421 110 113 C(24)–S(22)–N(23) 109.4617 –
9 H(99)–C(48)–C(47) 109.5 110 114 C(24)–S(22)–O(21) 109.462 –
10 H(98)–C(47)–H(97) 109.52 109.4 115 N(23)–S(22)–O(21) 109.4999 –
11 H(98)–C(47)–C(48) 109.4621 109.41 116 C(29)–C(24)–C(25) 120.003 120
12 H(98)–C(47)–C(46) 109.4616 109.41 117 C(29)–C(24)–S(22) 119.9984 –
13 H(97)–C(47)–C(48) 109.4421 109.41 118 C(25)–C(24)–S(22) 119.9986 –
14 H(97)–C(47)–C(46) 109.4417 109.41 119 H(81)–C(25)–C(26) 120.0013 120
15 C(48)–C(47)–C(46) 109.4999 109.5 120 H(81)–C(25)–C(24) 120.0016 120
16 H(80)–N(23)–H(79) 119.9998 104.5 121 C(26)–C(25)–C(24) 119.9971 –
17 H(80)–N(23)–S(22) 120.0004 – 122 H(83)–C(28)–C(29) 120.0016 120
18 H(79)–N(23)–S(22) 119.9997 – 123 H(83)–C(28)–C(27) 120.0016 120
19 H(78)–C(20)–H(77) 109.5202 109 124 C(29)–C(28)–C(27) 119.9968 –
20 H(78)–C(20)–H(76) 109.462 109 125 H(82)–C(26)–C(27) 119.999 120
21 H(78)–C(20)–C(19) 109.4612 110 126 H(82)–C(26)–C(25) 119.9999 120
22 H(77)–C(20)–H(76) 109.4424 109 127 C(27)–C(26)–C(25) 120.0011 –
23 H(77)–C(20)–C(19) 109.4416 110 128 C(55)–N(59)–C(45) 123.1877 –
24 H(76)–C(20)–C(19) 109.4999 110 129 C(55)–N(59)–Cu(1) 123.1876 –
25 H(75)–C(19)–H(74) 109.5197 109.4 130 C(45)–N(59)–Cu(1) 113.6247 –
26 H(75)–C(19)–C(20) 109.4619 109.41 131 H(60)–O(37)–C(36) 125.2505 –
27 H(75)–C(19)–C(18) 109.4616 109.41 132 H(60)–O(37)–Cu(1) 125.2498 –
28 H(74)–C(19)–C(20) 109.4421 109.41 133 C(36)–O(37)–Cu(1) 109.4997 –
29 H(74)–C(19)–C(18) 109.442 109.41 134 N(31)–C(27)–C(28) 119.9987 120
30 C(20)–C(19)–C(18) 109.5002 109.5 135 N(31)–C(27)–C(26) 119.9992 120
31 H(107)–C(57)–C(56) 120.0002 120 136 C(28)–C(27)–C(26) 120.0022 120
32 H(107)–C(57)–C(52) 120.0002 120 137 N(59)–Cu(1)–O(37) 109.3273 –
33 C(56)–C(57)–C(52) 119.9996 – 137 N(59)–Cu(1)–N(31) 109.5001 –
34 O(58)–S(50)–C(52) 109.5198 – 139 N(59)–Cu(1)–O(9) 109.5 –
35 O(58)–S(50)–N(51) 109.4417 – 140 N(59)–Cu(1)–Cl(3) 136.5963 –
36 O(58)–S(50)–O(49) 109.4419 116.6 141 N(59)–Cu(1)–Cl(2) 43.1572 –
37 C(52)–S(50)–N(51) 109.462 – 142 O(37)–Cu(1)–N(31) 109.5 –
38 C(52)–S(50)–O(49) 109.4616 – 143 O(37)–Cu(1)–O(9) 109.4998 –
39 N(51)–S(50)–O(49) 109.5003 – 144 O(37)–Cu(1)–Cl(3) 55.6453 –
40 C(57)–C(52)–C(53) 120.0026 120 145 O(37)–Cu(1)–Cl(2) 124.32 –
41 C(57)–C(52)–S(50) 119.9987 – 146 N(31)–Cu(1)–O(9) 109.5 –
42 C(53)–C(52)–S(50) 119.9986 – 147 N(31)–Cu(1)–Cl(3) 113.9036 –
43 H(104)–C(53)–C(54) 120.0016 120 148 N(31)–Cu(1)–Cl(2) 66.3429 –
44 H(104)–C(53)–C(52) 120.0013 120 149 O(9)–Cu(1)–Cl(3) 55.4536 –
45 C(54)–C(53)–C(52) 119.9972 – 150 O(9)–Cu(1)–Cl(2) 124.512 –
45 H(106)–C(56)–C(57) 120.0012 120 151 Cl(3)–Cu(1)–Cl(2) 179.7535 –
47 H(106)–C(56)–C(55) 120.0012 120 152 H(73)–C(18)–H(72) 109.5198 109.4
48 C(57)–C(56)–C(55) 119.9975 – 153 H(73)–C(18)–C(19) 109.4616 109.41
49 H(105)–C(54)–C(55) 119.9997 120 154 H(73)–C(18)–C(17) 109.4619 109.41
50 H(105)–C(54)–C(53) 119.9992 120 155 H(72)–C(18)–C(19) 109.4419 109.41
51 C(55)–C(54)–C(53) 120.0011 – 156 H(72)–C(18)–C(17) 109.4421 109.41
52 H(90)–C(42)–C(43) 120.0015 120 157 C(19)–C(18)–C(17) 109.5001 109.5
53 H(90)–C(42)–C(41) 120.0009 120 158 C(27)–N(31)–C(17) 137.567 –
54 C(43)–C(42)–C(41) 119.9975 – 159 C(27)–N(31)–Cu(1) 137.5671 –
55 H(89)–C(41)–C(42) 119.9991 120 160 C(17)–N(31)–Cu(1) 84.8659 –
56 H(89)–C(41)–C(40) 119.9996 120 161 H(67)–C(14)–C(15) 120.0016 120
57 C(42)–C(41)–C(40) 120.0013 – 162 H(67)–C(14)–C(13) 120.0011 120
58 H(88)–C(40)–C(41) 119.9991 120 163 C(15)–C(14)–C(13) 119.9973 –
59 H(88)–C(40)–C(39) 119.9988 120 164 H(66)–C(13)–C(14) 119.999 120
60 C(41)–C(40)–C(39) 120.0021 – 165 H(66)–C(13)–C(12) 119.9987 120
61 H(91)–C(43)–C(42) 119.9999 120 166 C(14)–C(13)–C(12) 120.0022 –
62 H(91)–C(43)–C(38) 120.0004 120 167 H(65)–C(12)–C(13) 119.9997 120
63 C(42)–C(43)–C(38) 119.9997 – 168 H(65)–C(12)–C(11) 119.9996 120
(continued on next page)
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Table 6 (continued)
Sr. No. Atoms Actual bond
angles
Optimal bond
angles
Sr. No. Atoms Actual bond
angles
Optimal bond
angles
64 H(87)–C(39)–C(40) 120.0019 120 169 C(13)–C(12)–C(11) 120.0007 –
65 H(87)–C(39)–C(38) 120.002 120 170 H(68)–C(15)–C(14) 120.0001 120
66 C(40)–C(39)–C(38) 119.9962 – 171 H(68)–C(15)–C(10) 120.0002 120
67 C(43)–C(38)–C(39) 120.0033 120 172 C(14)–C(15)–C(10) 119.9997 –
68 C(43)–C(38)–N(32) 119.9985 120 173 H(64)–C(11)–C(12) 120.0015 120
69 C(39)–C(38)–N(32) 119.9983 120 174 H(64)–C(11)–C(10) 120.0015 120
70 H(94)–C(44)–H(93) 109.52 109 175 C(12)–C(11)–C(10) 119.997 –
71 H(94)–C(44)–H(92) 109.4617 109 176 N(31)–C(17)–C(18) 127.0442 115.1
72 H(94)–C(44)–C(34) 109.4618 110 177 N(31)–C(17)–C(7) 105.9115 115.1
73 H(93)–C(44)–H(92) 109.4421 109 178 C(18)–C(17)–C(7) 127.0443 117.2
74 H(93)–C(44)–C(34) 109.4416 110 179 H(61)–O(9)–C(8) 125.2502 –
75 H(92)–C(44)–C(34) 109.5 110 180 H(61)–O(9)–Cu(1) 125.2501 –
76 C(34)–N(33)–N(32) 114.9101 115 181 C(8)–O(9)–Cu(1) 109.4997 –
77 C(38)–N(32)–C(36) 124.5 108 182 H(63)–C(8)–O(9) 108.4684 106.7
78 C(38)–N(32)–N(33) 124.5002 124 183 H(63)–C(8)–C(7) 114.5222 109.39
79 C(36)–N(32)–N(33) 110.9998 – 184 H(63)–C(8)–N(4) 111.7238 107.5
80 H(86)–C(36)–O(37) 108.4686 106.7 185 O(9)–C(8)–C(7) 107.5003 107.7
81 H(86)–C(36)–C(35) 114.5224 109.39 186 O(9)–C(8)–N(4) 110.5 –
82 H(86)–C(36)–N(32) 111.7236 107.5 187 C(7)–C(8)–N(4) 104.0001 –
83 O(37)–C(36)–C(35) 107.5001 107.7 188 C(15)–C(10)–C(11) 120.003 120
84 O(37)–C(36)–N(32) 110.5001 – 189 C(15)–C(10)–N(4) 119.9984 120
85 C(35)–C(36)–N(32) 104.0001 – 190 C(11)–C(10)–N(4) 119.9986 120
86 C(44)–C(34)–C(35) 127.9431 117.2 191 H(71)–C(16)–H(70) 109.5201 109
87 C(44)–C(34)–N(33) 127.9432 115.1 192 H(71)–C(16)–H(69) 109.4621 109
88 C(35)–C(34)–N(33) 104.1137 115.1 193 H(71)–C(16)–C(6) 109.4619 110
89 H(96)–C(46)–H(95) 109.52 109.4 194 H(70)–C(16)–H(69) 109.4416 109
90 H(96)–C(46)–C(47) 109.4615 109.41 195 H(70)–C(16)–C(6) 109.4419 110
91 H(96)–C(46)–C(45) 109.4621 109.41 196 H(69)–C(16)–C(6) 109.4997 110
92 H(95)–C(46)–C(47) 109.4418 109.41 197 H(62)–C(7)–C(17) 107.8496 109.39
93 H(95)–C(46)–C(45) 109.4419 109.41 198 H(62)–C(7)–C(8) 112.9888 109.39
94 C(47)–C(46)–C(45) 109.5 109.5 199 H(62)–C(7)–C(6) 112.9887 109.39
95 H(85)–C(35)–C(45) 107.8499 109.39 200 C(17)–C(7)–C(8) 109.4697 109.51
96 H(85)–C(35)–C(36) 112.9883 109.39 201 C(17)–C(7)–C(6) 109.4699 109.51
97 H(85)–C(35)–C(34) 112.9885 109.39 202 C(8)–C(7)–C(6) 103.9999 109.51
98 C(45)–C(35)–C(36) 109.4701 109.51 203 C(10)–N(4)–C(8) 124.5001 108
99 C(45)–C(35)–C(34) 109.4701 109.51 204 C(10)–N(4)–N(5) 124.4997 124
100 C(36)–C(35)–C(34) 103.9998 109.51 205 C(8)–N(4)–N(5) 111.0002 –
101 N(59)–C(55)–C(56) 119.9991 120 206 C(16)–C(6)–C(7) 129.5073 117.2
102 N(59)–C(55)–C(54) 119.9989 120 207 C(16)–C(6)–N(5) 129.5075 115.1
103 C(56)–C(55)–C(54) 120.002 120 208 C(7)–C(6)–N(5) 100.9853 115.1
104 N(59)–C(45)–C(46) 123.8198 115.1 209 C(6)–N(5)–N(4) 113.9712 115
105 N(59)–C(45)–C(35) 112.36 115.1
152 R.C. Maurya et al.at 400–441 nm in these complexes may also be considered as
the metal-ligand charge transfer transition as reported else-
where in case of the axially distorted octahedral (Jaskova
et al., 2007) copper(II) complexes. The electronic spectrum of
compound (1) is given in Fig. 5.
3.4. Thermogravimetric studies
Thermogravimetric curves of two compounds [Cu(bumphp-
smzH)2(Cl)2](1) (Fig. 6) and [Cu(bumphp-smxH)2(Cl)2] (4)
(Fig. 7) were recorded in the temperature range from room
temperature to 1300 C. Both compounds are stable up to
200 C. This excludes the possibility of lattice as well as
coordinated water molecule(s) in these two complexes. The
compound (4) shows a ﬁrst weight loss of 43.03% at around
300 C and this corresponds to the elimination of one molecule
of sulfa Schiff base ligand (calcd 43.99%). The second weightloss of 86.5% observed around 600 C in this compound cor-
responds to the elimination of second molecule of the sulfa
Schiff base ligand (calcd 87.9%). Compound (1) shows weight
losses in two steps and the total observed weight loss of 84%
around 750 C roughly corresponds to the elimination of two
molecules of the sulfa Schiff base ligand of this complex (calcd
87.68%). Thus, the overall the thermogravimetric results are
consistent with the formulation of these complexes along with
the conclusion derived from infrared spectral studies (vide
supra).
3.5. Magnetic susceptibility
The copper(II) has d9 electronic conﬁguration and its com-
plexes contain one unpaired electron in the d-shell. A majority
of complexes are formed by the involvement of d-orbital and
they are square planar or distorted octahedral. The John
Figure 9 Proposed octahedral structure of complexes.
Synthesis, characterization, and 3D-molecular modeling and analysis of some copper(II) chelates 153Teller distortions contribute a major role in the distortion of
the geometry of the complexes. The formation of tetrahedral
complexes of copper(II), with no involvement of d-orbital is
also reported to be formed. When the Cu(II) complexes display
magnetic moment values equivalent to one unpaired electron,
the complexes are referred to as magnetically dilute. In such
complexes the paramagnetic metal centers are situated apart
and the metal ions are surrounded by the ligand molecules in
such a way that unpaired spins of the neighboring metal ions
remain unaffected. In case of tetrahedral or distorted octahe-
dral Cu(II) complexes the room temperature magnetic moment
values are usually observed in the range of 1.8–2.2 BM, which
are not affected appreciably by temperature and magnetic
ﬁeld. In case of planar dimeric or polynuclear species, the com-
plexes display subnormal magnetic moments. In practice, com-
pounds whose geometry approaches an octahedral geometry
usually exhibit magnetic moments at the lower end, while those
approaching a tetrahedral geometry are at the higher end. In
the present investigations complexes exhibit magnetic moment
1.81–186 BM. These data indicate the octahedral (Maurya
et al., 2003) geometry for these compounds.
3.6. 3D Molecular modeling and analysis
In view of the hexa-coordination of the present complexes
(vide infra), and also taking into account of the well estab-
lished hexa-coordinate octahedral structure of
[Cu(en)2(H2O)2]
2+ cation (Jaskova et al., 2007) ([having neu-
tral bidentate (N,N-donor) ‘‘en’’ ligands similar to neutral
(O,N)-donor sulfa drug based Schiff base ligands in the present
investigation], wherein four nitrogen atoms of the ethylene-
diamine (en) form the coordination plane around the
copper(II) atom with the oxygen atoms of the two water
molecules lying in the axial positions, the molecular modeling
of a representative compound, [Cu(bumphp-snmH)2(Cl)2] (3)
with two Cl groups at the axial position trans to each other
and the two (O,N)-donor sulfa drug based Schiff base ligands
at the equatorial positions in cis-arrangement to each other,
is based on its octahedral structure. The details of bond
lengths and bond angles as per the 3D structure (Fig. 8)
are given in Tables 5 and 6, respectively. For convenience
of looking over the different bond lengths and bond angles,
the various atoms of the compound in question are numbered
in Arabic numerals. In all, 323 measurements of the bond
lengths (114 in numbers), plus the bond angles (209 in num-
bers) are listed. Except few cases, optimal values of both the
bond lengths and the bond angles are given in the tables
along with the actual ones. The actual (calculated) bond
lengths/bond angles given in tables are obtained as a result
of energy optimization in CHEM 3D Ultra, while the optimal
bond length/optimal bond angle values are the most desir-
able/favorable (standard) bond lengths/bond angles estab-
lished by the builder unit of the CHEM 3D. The missing
of some values of optimal bond lengths/bond angles may
be due to the limitations of the software, which we had
already noticed in modeling of other systems (Maurya and
Rajput, 2007; Maurya et al., 2007, 2008). In most of the
cases, the calculated bond lengths and bond angles are close
to the optimal values, and thus the proposed structure of the
compound (3) as well as of the others are acceptable (Maurya
and Rajput, 2007; Maurya et al., 2007, 2008, 2011).4. Conclusions
The satisfactory analytical data and all the studies presented
above indicate that the copper(II) complexes in the present
investigation may be formulated as [Cu(LH)2(Cl)2], where
LH = N-(40-butyrylidine-30-methyl-10-phenyl-20-pyrazolin-50-
one)sulfamethoxazole (bumphp-smzH), N-(40-butyrylidine-30-
methyl-10-phenyl-20-pyrazolin-50-one)sulfadimidine (bumphp-
sdmH), N-(4’-butyrylidine-30-methyl-10-phenyl-20-pyrazolin-50-
one)sulfanilamide (bumphp-snmH), N-(40-butyrylidine-30-
methyl-10-phenyl-20-pyrazolin-50-one)sulfamoxole (bumphp-
sml) or N-(40-butyrylidine-30-methyl-10-phenyl-20-pyrazolin-50-
one)sulfaguanidine (bumphp-sgd). Keeping in view of the
non-electrolytic (Geary, 1971) nature of the complexes
(Km = 7.2–10.8 ohm
1 cm2 mol1), IR, ESR, magnetic, and
electronic spectral results, and also considering the well estab-
lished axially distorted octahedral structure of
[Cu(en)2(H2O)2]
2+ cation (Jaskova et al., 2007), wherein four
nitrogen atoms of the ethylenediamine (en) form the coordina-
tion plane around the copper(II) atom with the oxygen atoms
of the two water molecules lying in the axial positions, axially
distorted octahedral structures (Fig. 9) having two Cl groups
at the axial position trans to each other, and the two (O,N)-
donor sulfa drug Schiff base ligands at the equatorial positions
in cis-arrangement have been proposed for these complexes. X-
ray crystallographic studies, which might conﬁrm the proposed
structures, could not be carried out, as suitable crystals could
not be grown.
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